Irina Rivkind Koffler
Stock Analyst at Mizuho
(0.48)
# 3,922
Out of 4,761 analysts
31
Total ratings
25%
Success rate
-16.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Irina Rivkind Koffler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Assumes: Buy | $30 | $13.99 | +114.44% | 4 | Sep 5, 2019 | |
| DERM Journey Medical | Upgrades: Buy | $17 → $14 | $5.19 | +169.75% | 4 | Jun 6, 2019 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Neutral | $146 → $148 | $136.01 | +8.82% | 6 | May 8, 2019 | |
| PCRX Pacira BioSciences | Upgrades: Neutral | $29 → $38 | $25.16 | +51.03% | 4 | May 6, 2019 | |
| SUPN Supernus Pharmaceuticals | Maintains: Buy | $61 → $63 | $33.05 | +90.62% | 2 | Dec 17, 2018 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $28 → $29 | $16.74 | +73.24% | 7 | Sep 17, 2018 | |
| IRWD Ironwood Pharmaceuticals | Upgrades: Buy | n/a | $1.82 | - | 4 | May 2, 2018 |
Evolus
Sep 5, 2019
Assumes: Buy
Price Target: $30
Current: $13.99
Upside: +114.44%
Journey Medical
Jun 6, 2019
Upgrades: Buy
Price Target: $17 → $14
Current: $5.19
Upside: +169.75%
Jazz Pharmaceuticals
May 8, 2019
Maintains: Neutral
Price Target: $146 → $148
Current: $136.01
Upside: +8.82%
Pacira BioSciences
May 6, 2019
Upgrades: Neutral
Price Target: $29 → $38
Current: $25.16
Upside: +51.03%
Supernus Pharmaceuticals
Dec 17, 2018
Maintains: Buy
Price Target: $61 → $63
Current: $33.05
Upside: +90.62%
Teva Pharmaceutical Industries
Sep 17, 2018
Maintains: Buy
Price Target: $28 → $29
Current: $16.74
Upside: +73.24%
Ironwood Pharmaceuticals
May 2, 2018
Upgrades: Buy
Price Target: n/a
Current: $1.82
Upside: -